Evidence map›Paper›PMID 40515594›Full record

ArticleOncoimmunology2025

Mutant p53-specific CD8TCR-therapy combined with a CD4TCR prevents relapse of cancer and outgrowth of micrometastases.

Vasiliki Anastasopoulou, Hans Schreiber, Ching-En Lee, Kazuma Kiyotani, Leo Hansmann, Yusuke Nakamura, Matthias Leisegang, Steven P Wolf

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Vasiliki AnastasopoulouInstitute of Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Hans SchreiberDavid and Etta Jonas Center for Cellular Therapy, The University of Chicago, Chicago, IL, USA.
Ching-En LeeDepartment of Pathology, The University of Chicago, Chicago, IL, USA.
Kazuma KiyotaniLaboratory of Immunogenomics, Center for Intractable Diseases and ImmunoGenomics (CiDIG), National Institute of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki-shi, Osaka, Japan.
Leo HansmannDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
Yusuke NakamuraLaboratory of Immunogenomics, Center for Intractable Diseases and ImmunoGenomics (CiDIG), National Institute of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki-shi, Osaka, Japan.
Matthias LeisegangInstitute of Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Steven P WolfDavid and Etta Jonas Center for Cellular Therapy, The University of Chicago, Chicago, IL, USA.

Funding

PATHOBIOLOGY OF MYELOMA AND ANTI-IDIOTYPIC IMMUNITYR01CA022677 · NCI · UNIVERSITY OF CHICAGO · PI SCHREIBER, HANS · 1985 to 2024
$6.3M
NCI NIH HHS R01 CA022677
6 · The paper itself

Abstract

Relapse remains challenging in the treatment of metastatic cancers. More than 50% of human cancers harbor mutant p53 (mp53) as a cancer-specific target. We present the spontaneously metastasizing tumor model Ag104A to advance mp53-specific T cell receptor engineered T cell therapy (TCR-therapy). We identified in Ag104A an autochthonous p53

Indexed as

CD4-Positive T-LymphocytesCD8-Positive T-LymphocytesImmunotherapy, AdoptiveNeoplasm Recurrence, LocalNeoplasmsReceptors, Antigen, T-CellTumor Suppressor Protein p53AnimalsAntigens, NeoplasmCell Line, TumorFemaleHumansMiceMutationNeoplasm MicrometastasisAntigens, NeoplasmReceptors, Antigen, T-CellTumor Suppressor Protein p53Adoptive cell transfermetastatic tumor modelmutant p53neoantigenTCR-therapy

Identifiers

PMID40515594
PMCPMC12169035

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.